Standing room only 6 am for the NCTN ⁦⁦Alliance for Clinical Trials in Oncology⁩ ⁦SWOG Cancer Research Network⁩ ⁦ECOG-ACRIN Cancer Research Group⁩ ⁦NRG⁩ meeting at #GU24 Thank you Officer ⁦Stephanie Berg⁩ for organizing ! ⁦Dana-Farber Lank Center for Genitourinary Oncology⁩

✨ASCO #GU24 lady gang always ready to support each other! Hematology & Oncology Women Physicians Group—HOWPG Stephanie Berg Tian Zhang, MD, MHS Rana McKay, MD, FASCO Tanya Dorff Andrea Apolo, M.D. Cristiane D Bergerot Maite Bourlon Elizabeth Plimack MD Ulka Vaishampayan Laurence Albiges Shilpa Gupta Cris KCCure Gretchen Vaughan Laura Bukavina

✨👩🏽‍⚕️First ASCO 's women in #GU24 women networking lunch So humbling and inspiring to meet some of the first women who paver the way for us OncoAlert

Financial toxicity is more than drug cost! When dx with cancer, half of pts stop or reduce saving for retirement, 15% sold homes or property, 25% borrowed from friends/family. We need to assess financial burden in #kidneycancer! #GU24

Starting off Day 3 #GU24 with a phenomenal presentation by Toni Choueiri, MD showing OS survival with pembrolizumab in the adjuvant setting👉First trial to show an improvement of OS in the adjuvant setting 👉 Benefit across all sub groups 👉 38% reduction in the risk of death

Yup. Per the latest ICH E9(R1) recs we need to carefully consider our estimands during both RCT design & transporting inferences for shared decision-making. Stay tuned for upcoming summary from #IKCS23 think tank 👉 database.ich.org/sites/default/… Stephanie Berg Tian Zhang, MD, MHS @kidneycancer

Less than a month 'til #KidneyCancerAwarenessMonth kicks off in March!!! Join us as we raise awareness, share stories of resilience, and #OrangeUp! kidneycancer.org/kidney-cancer-… Follow along, share, or comment how you plan to get involved. 🧡⤵️

1/ The long-awaited OS results from #KEYNOTE-564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…

My top themes of #ASCO24 for #kidneycancer, #prostatecancer, #bladdercancer, & #DevelopmentalIO -- scratches only the surface of the bountiful harvest of ASCO trials!! Looking forward to seeing/hearing from colleagues from around the world ASCO ESMO - Eur. Oncology OncoAlert

Fantastic meeting of IMG Oncologists (37% of practicing oncologists in USA) steered by Toni Choueiri, MD Ziad Bakouny, MD, MSc Nazli Dizman 👉Challenges faced by IMGs, Insights from the 2023 meeting, how to join the group👇ASCO #ASCO24 #IMGCoP meeting overview 👇OncoAlert #ASCODailyNews

What an incredible ASCO IMG Community of Practice session it was! Thanks to all the speakers and everyone who joined. Looking forward to #ASCO25 already! #ASCO24 Nazli Dizman Toni Choueiri, MD Karun Neupane, MD Lei Deng, MD (He/Him) Neeraj Agarwal, MD, FASCO Tanios Bekaii-Saab, MD Narjust Florez, MD, FASCO Sumanta K. Pal, MD, FASCO

Biomarker data from KN426 (axi/pembro vs sunitinib) in 1st line RCC. Within arm analysis show T cell signature ⬆️ responses for axi/pembro while angiogenic signatures ⬆️ sunitinib.RNA clusters didn’t define winners. DNA/PD-L1 not helpful. VEGF in both arms is problematic #ASCO24

Deep dive of gender equity at ASCO & #ASCOGI by Rachna Shroff, MD, MS, FASCO at #ASCO24. While moderators/discussants balanced thanks to efforts from ASCO, disparities exist in original research abstract presentations. Have thought about this a lot. There’s unlikely a singular solution but

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussion by Wenxin (Vincent) Xu (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with Laurence Albiges spotifyanchor-web.app.link/e/9vRDmeiGeKb

Looking forward to a terrific meeting - starting tomorrow! Many thanks to the group below for helping bring forward lots of groundbreaking research.

#KCRS24 is officially kicking off! 🏁 Participants are registering, and our speakers are gearing up to share groundbreaking research and insights. Stay tuned for an exciting two days of innovation and collaboration in kidney cancer research! #KidneyCancer #AcceleratingCures

#KCRS24 KidneyCAN STARTING!! Let’s cure #kidneycancer thank you to entire kidney cancer community !

Excited to attend #KCRS24 KidneyCAN ! Bryan Lewis starting us off. Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber News

Michael Serzan, MD discusses the #ARCITECT trial in progress — botensilimab and balstilimab combination vs ipi-nivo in frontline #kidneycancer — open UTSW Simmons Cancer Center! Just gave a consent yesterday.

Giants on stage discussing the latest updates in clinical trials in mRCC. #KCRS24 Toni Choueiri, MD David Braun Rana McKay, MD, FASCO Laurence Albiges Bradley McGregor Tom Powles Robert Motzer MD